Inclement weather can pose a threat to people like columnist Ari Anderson, who depend on in-home care. Such are the storms of ...

In a report released today, David Amsellem from Piper Sandler maintained a Hold rating on Biogen (BIIB – Research Report), with a price target ...

It was a busy week for the biotech sector, with regulatory and pipeline updates. Sage Therapeutics SAGE was in focus after it ...

Total proceeds of $530 million on $300 million original 2022 investment Proceeds strengthen balance sheet and provide added flexibility to pursue disciplined capital allocation strategy, including sig ...

Total proceeds of $530 million on $300 million original 2022 investment Proceeds strengthen balance sheet and provide added flexibility to pursue ...

Biogen has announced that the European Medicines Agency (EMA) and US Food and Drug Administration (FDA) have started ...

Donald Trump continues to make waves in biopharma; Sage rejects Biogen’s unsolicited takeover offer; the obesity space sees ...

The financial challenges facing clinical trials have created a more risk-averse landscape. Yet digital solutions could be the key for sponsors and CROs to optimize budgets and resources. We explore ...

Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatment Alzheimer's disease progression does not stop after plaque clearance; ongoing treatment with ...

Application is supported by results from the DEVOTE study, which suggested that two doses of Spinraza (nusinerse) 50 mg taken ...

Regulators in the U.S. and the European Union agreed to review Biogen’s applications for approval of a higher dose Spinraza ...

Biogen BIIB announced that the FDA and EMA have accepted its regulatory filings seeking label expansion for a higher dose of ...